Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Enzyme Replacement Therapy Market

Enzyme Replacement Therapy Market Share

Report ID: GMI6680
Published Date: Sep 2023
Report Format: PDF

Download Free Sample

Enzyme Replacement Therapy Market Share

The well known, established, prominent players in enzyme replacement therapy market are:

Sanofi
Biomarin Pharmaceutical Inc
AbbVie Inc
Pfizer, Inc
Alexion Pharmaceuticals Inc
Allergan plc
Horizon Pharma Public Limited Company
Recordati Rare Diseases
Protalix Biotherapeutics
Amicus Therapeutics

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global market size for enzyme replacement therapy (ERT) was valued at USD 10 billion in 2023 and is expected to reach USD 18.6 billion by 2032, backed by the rising prevalence of rare genetic disorders, including LSDs such as gaucher disease, fabry disease, pompe disease, and mucopolysaccharidosis (MPS).

The agalsidase beta segment accounted for 8.7% market share in 2022 as the enzyme demonstrates efficacy in reducing the accumulation of Gb3 and related substances in various organs and tissues.

North America market is expected to record a CAGR of 7.2% from 2023-2032 as the region has a relatively high prevalence of rare genetic disorders, including Gaucher disease, Fabry disease, Pompe disease, and mucopolysaccharidosis (MPS).

Sanofi, Biomarin Pharmaceutical Inc., AbbVie Inc., Pfizer, Inc., Alexion Pharmaceuticals Inc., Allergan plc, Horizon Pharma Public Limited Company, Recordati Rare Diseases, Protalix Biotherapeutics, and Amicus Therapeutics, Inc.